Pulse Biosciences Inc
$ 38.24
0.90%
06 Aug - close price
- Market Cap 2,623,048,000 USD
- Current Price $ 38.24
- High / Low $ 39.12 / 37.65
- Stock P/E N/A
- Book Value 0.97
- EPS -1.10
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -0.81 %
- 52 Week High 39.09
- 52 Week Low 12.56
About
Pulse Biosciences, Inc. is a bioelectrical medicine startup. The company is headquartered in Hayward, California.
Analyst Target Price
$32.33
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-04 | 2026-02-19 | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-12 | 2024-05-07 | 2024-03-28 | 2023-11-13 |
| Reported EPS | -0.28 | -0.2414 | -0.18 | -0.29 | -0.28 | -0.2502 | -0.3124 | -0.2076 | -0.1991 | -0.18 | -0.2167 | -0.19 |
| Estimated EPS | -0.31 | -0.22 | -0.21 | -0.31 | -0.26 | None | -0.24 | -0.24 | -0.2 | -0.24 | -0.24 | -0.22 |
| Surprise | 0.03 | -0.0214 | 0.03 | 0.02 | -0.02 | 0 | -0.0724 | 0.0324 | 0.0009 | 0.06 | 0.0233 | 0.03 |
| Surprise Percentage | 9.6774% | -9.7273% | 14.2857% | 6.4516% | -7.6923% | None% | -30.1667% | 13.5% | 0.45% | 25% | 9.7083% | 13.6364% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PLSE
2026-08-07 07:41:15
Pulse Biosciences (PLSE) reported a Q2 loss of $0.36 per share, missing the Zacks Consensus Estimate of a $0.31 loss and underperforming the previous year's loss of $0.28 per share. The company also missed revenue estimates, posting $0.43 million against a 38% higher Zacks Consensus Estimate. Despite the Q2 misses, PLSE shares have seen a significant 176% increase year-to-date, significantly outperforming the S&P 500's 12.8% gain.
2026-08-07 06:42:15
Pulse Biosciences (PLSE) reported its Q2 2026 earnings, highlighting significant progress in its NANOPULSE-AF pivotal study, which is ahead of schedule with over 82 evaluable patients. The company strengthened its balance sheet with $101.6 million in cash, extending its financial runway through key clinical and regulatory milestones. Despite increased spending due to accelerated clinical and product development, positive clinical and workflow feedback for its nPulse cardiac catheter suggests strong market adoption potential.
2026-08-07 04:41:14
Pulse Biosciences Inc (PLSE) reported accelerated enrollment in its NanoPulse-AF IDE study, reaching the halfway point ahead of schedule, with strong feasibility data presented at HRS. The company strengthened its balance sheet by raising $57.5 million, extending its financial runway, and is progressing multiple programs including a surgical clamp and the Vibrance thyroid system. Despite these positive developments, PLSE continues to incur significant operating losses and faces challenges related to increased enrollment targets, reliance on limited clinical sites, lengthy regulatory approval timelines, minimal revenue generation, and shareholder dilution from capital raising.
2026-08-07 03:41:15
Pulse Biosciences reported a wider-than-expected Q2 2026 loss and lower revenue but saw its stock rise after hours due to accelerated enrollment in its atrial fibrillation trial, a stronger cash position, and progress in its thyroid and surgical programs. The company's nanosecond pulsed field ablation (nsPFA) technology is showing promising clinical results, particularly in its cardiac catheter program, with enrollment ahead of schedule and strong physician enthusiasm. Despite the earnings miss, investors are focusing on the company's clinical execution and long-term potential in a complex capital-raising environment.
2026-08-06 20:41:14
Pulse Biosciences, Inc. (PLSE) reported its Q2 revenue at $0.4 million, falling short of FactSet's estimated $533K. The company's stock, PLSE, is listed on Nasdaq in the Advanced Medical Equipment & Technology sector. The article also highlights recent news, including their Q2 earnings call, progress in a pivotal study, and analyst rating adjustments.
2026-08-06 18:42:23
Pulse Biosciences Inc. is expected to report its second-quarter results after market close on Thursday, with investors keenly watching the performance of its Nanosecond Pulsed Field Ablation (PFA) technology. Analysts anticipate a loss of 29 cents per share on revenue of $533,330, reflecting sequential revenue growth but a wider loss compared to the previous quarter. The focus will be on whether the strong clinical data from initial studies can be replicated in larger pivotal trials and the trajectory of commercial adoption for its novel technology.
